IN2012MN02812A - - Google Patents

Info

Publication number
IN2012MN02812A
IN2012MN02812A IN2812MUN2012A IN2012MN02812A IN 2012MN02812 A IN2012MN02812 A IN 2012MN02812A IN 2812MUN2012 A IN2812MUN2012 A IN 2812MUN2012A IN 2012MN02812 A IN2012MN02812 A IN 2012MN02812A
Authority
IN
India
Prior art keywords
interleukin
growth factor
alpha
apolipoprotein
insulin
Prior art date
Application number
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of IN2012MN02812A publication Critical patent/IN2012MN02812A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 as diagnostic and prognostic biomarkers in renal injuries.
IN2812MUN2012 2010-06-23 2011-06-23 IN2012MN02812A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35795610P 2010-06-23 2010-06-23
US35796510P 2010-06-23 2010-06-23
US35796610P 2010-06-23 2010-06-23
US36429610P 2010-07-14 2010-07-14
US36430510P 2010-07-14 2010-07-14
PCT/US2011/001125 WO2011162819A1 (en) 2010-06-23 2011-06-23 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
IN2012MN02812A true IN2012MN02812A (en) 2015-05-22

Family

ID=45371737

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2812MUN2012 IN2012MN02812A (en) 2010-06-23 2011-06-23

Country Status (7)

Country Link
US (4) US20130203074A1 (en)
EP (2) EP3339859A1 (en)
AU (1) AU2011269847A1 (en)
CA (1) CA2803498A1 (en)
IN (1) IN2012MN02812A (en)
NZ (2) NZ605561A (en)
WO (1) WO2011162819A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201214440D0 (en) * 2012-08-13 2012-09-26 Randox Lab Ltd Kidney disease biomarker
ES2907551T3 (en) 2014-10-20 2022-04-25 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of kidney injury and kidney failure
US11143658B2 (en) 2015-05-12 2021-10-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA3049444A1 (en) 2017-01-12 2018-07-19 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1429031A1 (en) 1986-06-20 1988-10-07 Калининский Государственный Медицинский Институт Method of differential analysis of glomerolonephritis and pyelonephritis
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
DE69228682T2 (en) 1991-04-10 1999-07-01 Biosite Diagnostics Inc "CROSSTALK" OR CROSS-CALL INHIBITORS AND THEIR USE
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
EA004402B1 (en) 1996-05-24 2004-04-29 Байоджен, Инк. Modulators of tissue regeneration
US5753455A (en) 1996-09-03 1998-05-19 Bayer Corporation Method for the detection of lysozyme using a protein error indicator dye in conjunction with an alkane sulfonic acid
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
CA2293296A1 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center Human proteins having transmembrane domains and dnas encoding these proteins
US20060223077A1 (en) 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
BR9916407A (en) 1998-12-21 2001-09-25 Univ Monash Detection and treatment of kidney disease
RU2180965C1 (en) 2000-07-03 2002-03-27 Габбасова Наталья Вадимовна Method of differentiated prediction of renal diseases
EP1405072A2 (en) 2000-12-29 2004-04-07 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030003588A1 (en) 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
KR20040053100A (en) 2001-07-24 2004-06-23 예일 유니버시티 Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
GB0130557D0 (en) 2001-12-20 2002-02-06 Serono Internat S A Proteins
WO2003075016A1 (en) 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
WO2003081201A2 (en) 2002-03-21 2003-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
US7138230B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US7138229B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US6941172B2 (en) 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
WO2004053074A2 (en) 2002-12-06 2004-06-24 Science And Technology Corporation @ Unm Outcome prediction and risk classification in childhood leukemia
JP5392980B2 (en) 2003-03-27 2014-01-22 チルドレンズ ホスピタル メディカル センター Method and kit for detecting early-onset renal tubular cell injury
CN1791797A (en) 2003-03-27 2006-06-21 儿童医院医疗中心 A method and kit for detecting the early onset of renal tubular cell injury
EP2316487B1 (en) 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
US7560244B2 (en) 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
EP1727564A1 (en) 2004-03-17 2006-12-06 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
EP1743031A4 (en) 2004-04-26 2008-05-28 Childrens Medical Center Platelet biomarkers for the detection of disease
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US20080038192A1 (en) 2004-07-19 2008-02-14 Neurochem Inc. Diagnostic Methods Of Multiple Organ Amyloidosis
US7588892B2 (en) 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
US20060134708A1 (en) 2004-10-14 2006-06-22 Northwestern University Detection and treatment of renal cancer
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
WO2006099421A2 (en) 2005-03-14 2006-09-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
CN103789405B (en) 2005-04-18 2018-03-30 Mdna生命科学有限公司 Mitochondrial mutations and rearrangement as the diagnostic tool of detection solar radiation, prostate cancer and other cancers
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
CA2614935A1 (en) 2005-07-21 2007-02-01 The Johns Hopkins University Methods of detecting and treating acute kidney injury
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
WO2007041623A2 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20080090304A1 (en) 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US10716749B2 (en) 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080038269A1 (en) 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
US20090298073A1 (en) 2006-06-30 2009-12-03 Gerhold David L Kidney Toxicity Biomarkers
US20090176656A1 (en) 2006-07-21 2009-07-09 Halloran Philip F Tissue rejection
GB0617429D0 (en) 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
US20080206794A1 (en) 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
EP2095107B1 (en) 2006-11-14 2014-07-02 Alere San Diego, Inc. Methods for risk assignment
EP2064550B1 (en) 2006-12-08 2015-02-25 The Children's Hospital Of Philadelphia Use of prrg4 in methods of tumor diagnosis
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
EP2479571A3 (en) 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
US20110129820A1 (en) 2007-04-10 2011-06-02 Integragen Human diabetes susceptibility tnfrsf10b gene
US8080394B2 (en) 2007-04-27 2011-12-20 Brigham And Women's Hospital Method for determining predisposition to pulmonary infection
US9091695B2 (en) 2007-06-01 2015-07-28 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
EP2160478B1 (en) 2007-06-06 2014-08-27 Siemens Healthcare Diagnostics Inc. Predictive diagnostics for kidney disease
US20090047689A1 (en) 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
US20100267041A1 (en) 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
EP2203743A4 (en) 2007-09-20 2011-03-02 Univ Louisville Res Found Peptide biomarkers predictive of renal function decline and kidney disease
US8003333B2 (en) 2007-09-28 2011-08-23 Mayo Foundation For Medical Education And Research Serum biomarkers for early detection of acute cellular rejection
US20110111427A1 (en) 2008-02-29 2011-05-12 Kenji Kadomatsu Biomarker for the estimation of acute renal disorder and prognosis of the disorder, and use of the biomarker
CN101358976A (en) 2008-04-28 2009-02-04 北京华大吉比爱生物技术有限公司 Micro array-ELISA detecting kit for detecting six tumor markers
US20090298106A1 (en) 2008-05-30 2009-12-03 Therapeutic Monitoring Services, L.L.C. Methods for Monitoring Immunosuppressant Drug Levels, Renal Function, and Hepatic Function Using Small Volume Samples
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
EP2149613A1 (en) 2008-07-28 2010-02-03 Greenwood Genetic Center, Inc. Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders
WO2010022210A2 (en) 2008-08-21 2010-02-25 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
NZ591437A (en) 2008-08-28 2013-07-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105021826A (en) 2008-08-29 2015-11-04 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8501489B2 (en) 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
EP3246707B1 (en) 2008-10-21 2020-09-30 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ592365A (en) 2008-10-21 2014-08-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ592488A (en) 2008-11-10 2012-10-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ604873A (en) 2008-11-22 2014-05-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120053072A1 (en) 2009-02-06 2012-03-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2427496A4 (en) 2009-04-03 2013-05-15 Vegenics Pty Ltd Anti-vegf-d antibodies
US20120183543A1 (en) 2009-05-08 2012-07-19 Novartis Ag Diagnostic biomarkers for fibrotic disorders
EP2462445A1 (en) 2009-08-07 2012-06-13 Rules-Based Medicine, Inc. Devices for detecting renal disorders
JP5775874B2 (en) 2009-08-28 2015-09-09 アスチュート メディカル，インコーポレイテッド Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2774223A1 (en) 2009-09-21 2011-03-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2592386T3 (en) 2009-12-20 2016-11-29 Astute Medical, Inc. Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
US9029093B2 (en) 2010-02-26 2015-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102539745B (en) 2010-12-31 2013-03-06 中国人民解放军第三〇九医院 Early diagnosis and early warning kit for transplanted kidney rejection reaction and detection method
US20130035290A1 (en) 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury

Also Published As

Publication number Publication date
NZ605561A (en) 2015-03-27
US20190265253A1 (en) 2019-08-29
EP2585825A4 (en) 2013-12-11
US10928403B2 (en) 2021-02-23
US20130203074A1 (en) 2013-08-08
WO2011162819A1 (en) 2011-12-29
NZ703055A (en) 2016-07-29
AU2011269847A1 (en) 2013-01-31
CA2803498A1 (en) 2011-12-29
EP3339859A1 (en) 2018-06-27
EP2585825A1 (en) 2013-05-01
US20210148937A1 (en) 2021-05-20
US20170261519A1 (en) 2017-09-14
EP2585825B1 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
Papadopoulou-Marketou et al. Biomarkers of diabetic nephropathy: A 2017 update
Romagnani et al. Cell cycle–dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity
MX2011004767A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
Tug et al. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage.
Asayama et al. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes
Ocejo-Vinyals et al. The IL-17 G-152A single nucleotide polymorphism is associated with pulmonary tuberculosis in northern Spain
EP2585826A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Dlouhy et al. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma
EA201290387A1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF KIDNEY DAMAGE AND RENAL FAILURE
MX2007008017A (en) Polypeptides that bind br3 and uses thereof.
MX2011002233A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
IN2014MN00377A (en)
JP2008249727A5 (en)
IN2012MN02812A (en)
EP2811036A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2009143519A3 (en) Biomarkers for myocardial ischemia
Lemancewicz et al. Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features
CA2886783A1 (en) Biomarkers and methods to predict response to inhibitors and uses thereof
EP2585827A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112013021056A2 (en) monoclonal antibody, hybridoma cell line, diagnostic kit, methods for producing a monoclonal antibody and binding agent, purified amino acid sequence binding agent, method for obtaining a coding nucleic acid sequence, antibody molecule encoding isolated nucleic acid, vector, isolated host cell, fusion protein, screening method for the presence of a disease, a condition, methods of diagnosing an individual, prognosis for an individual, and monitoring an individual, and , method for detecting the presence or absence of cervical cancer
NZ599773A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2007514651A5 (en)
NZ598035A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Lopotová et al. Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs
EA201290627A1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF KIDNEY DAMAGE AND RENAL FAILURE